Bristol-Myers buys experimental drug rights

The folks at Bristol-Myers Squibb have apparently been shopping: the company will buy the rights for an experimental antibody called elotuzumab from PDL BioPharma. The deal also provides an option to expand the relationship to include PDL241, an additional experimental drug for immunologic indications in the future.

The company will pay $30 million for what it hopes will be a successful multiple myeloma treatment. Multiple myeloma is a type of blood cancer, and the drug is currently in Phase I trials.  If the drug meets predetermined development and sales targets, there could be up to $680 million in further payments for PDL.

Bristol-Myers will provide 80 percent of the funds to develop the treatment, with PDL covering the remaining 20 percent.  They will share drug profits in the U.S., but PDL will retain the rights to profits outside of the country. 

-- check out the Bristol-Myers Squibb release
--read the story at CNN Money
--see more at Forbes

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.